Cancer Care

 

 

Lung / Esophageal / Thoracic Cancer Clinical Trials

A clinical trial is one of the final steps in a long and careful cancer research process that is looking for better ways to prevent, diagnose, or treat cancer. Clinical trials test new medical approaches in patients with cancer, and are important to developing new treatments for cancer. Many of the "standard treatments" that patients with cancer receive today were developed based on the results of previous clinical trials.

The following is a list of clinical trials with which this cancer care program is currently involved. Talk to your doctor to find out if a clinical trial is right for you.

Esophagus Clinical Trials
A Phase III Trial Evaluating the Addition of Cetuximab to Paclitaxel, Cisplatin, and Radiation for Patients With Esophageal Cancer Who Are Treated Without Surgery
Esophagus
R0436
Hartford
Reducing Disparities in Health for Vulnerable Populations in NH and VT: Journey Forward Cancer Survivor Care Planning in the Rural Northeast
Esophagus
FED11061
Pace
Lung Clinical Trials
A Phase II study of the BRAF inhibitor dabrafenib as a single agent and in combination with the MEK inhibitor trametinib in subjects with BRAF V600E mutation positive metastatic (stage IV) non-small cell lung cancer
Lung
F12214
Rigas
A Phase II, Multicenter, Single-Arm Study of MPDL2380A in Patients With PD-L1-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Lung
F14003
Rigas
A Randomized Phase III Double-Blind Trial Evaluating Selective COX-2 Inhibition In COX-2 Expressing Advanced Non-Small Cell Lung Cancer
Lung
C30801
Dragnev
A Randomized, Open-Label Phase 2 Study Evaluating LY2875358 Plus Erlotinib and LY2875358 Monotherapy in MET Diagnostic Positive NSCLC Patients with Acquired Resistance to Erlotinib
Lung
F13118
Dragnev
A Randomized, Phase III Study Comparing Carboplatin/Paclitaxel Or Carboplatin/Paclitaxel/Bevacizumab With Or Without Concurrent Cetuximab In Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
Lung
S0819
Howard
A Study of HSP90 Inhibitor AT13387 Alone and in Combination with Crizotinib in the Treatment of Non-Small Cell Lung Cancer (NSCLC)
Lung
F12200
Dragnev
Phase III Trial Of Dose Escalated Radiation Therapy And Standard Androgen Deprivation Therapy (ADT) With A GNRH Agonist VS. Dose Escalated Radiation Therapy And Enhanced ADT With A GNRH Agonist And TAK-700 For Men With High Risk Prostate Cancer
Lung
R1115
Hartford
Phosphoproteomic Patterns as a Novel Biomarker for Aurora and Polo-like Kinase Inhibitors in Non-Small Cell Lung Cancer
Lung
D1026
Rigas
RTOG 0925: Natural History of Postoperative Cognitive Function, Quality of Life, and Seizure Control in Patients with Supratentorial Low-Risk Grade II Glioma
Lung
R0925
Hartford
Reducing Disparities in Health for Vulnerable Populations in NH and VT: Journey Forward Cancer Survivor Care Planning in the Rural Northeast
Lung
FED11061
Pace
SUNRISE: A Phase III, Randomized, Double-Blind, Placebo-Controlled Multicenter Trial of Bavituximab Plus Docetaxel versus Docetaxel Alone as Second-Line Therapy in Patients with Stage IIIb/IV Non-Squamous Non-Small-Cell Lung Cancer
Lung
F14009
Dragnev
Other Respiratory and Intrathoracic Organs Clinical Trials
Reducing Disparities in Health for Vulnerable Populations in NH and VT: Journey Forward Cancer Survivor Care Planning in the Rural Northeast
Other Respiratory and Intrathoracic Organs
FED11061
Pace